T. Rowe Price Associates’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-885,332
| Closed | -$95M | – | 2993 |
|
|
2023
Q1 | $95M | Buy |
885,332
+430,273
| +95% | +$46.2M | 0.01% | 520 |
|
|
2022
Q4 | $50.1M | Buy |
455,059
+359,970
| +379% | +$39.6M | 0.01% | 660 |
|
|
2022
Q3 | $5.61M | Buy |
+95,089
| New | +$5.61M | ﹤0.01% | 1177 |
|
|
2021
Q2 | – | Sell |
-525,000
| Closed | -$9.59M | – | 2956 |
|
|
2021
Q1 | $9.59M | Buy |
+525,000
| New | +$9.59M | ﹤0.01% | 1400 |
|